All In Biotech

Drug Trial Radar · NCT06775483

Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance: a Phase II Clinical Study

Last checked: Nov 20, 2026Latest source record: Jan 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

220

Planned (sponsor's estimate)

Start

Jan 17, 2025

Primary completion

Jun 30, 2027

Study completion Nov 30, 2027

Sponsor

Sponsor type
Industry
First posted
Jan 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II clinical study conducted in China to evaluate the treatment of advanced non-small cell lung cancer with JSKN016. The enrolled subjects are all in the locally advanced or metastatic stage of non-small cell lung cancer.The study is divided into two parts. The main objective of part I is to assess the efficacy and safety of JSKN016 in selected subjects with advanced non-small cell lung cancer. The main objective of part II is to compare the efficacy of JSKN016 and docetaxel in subjects with advanced non-small cell lung cancer.

Conditions

  • Advanced Non-small Cell Lung Cancer

Interventions

  • JSKN016Drug

    Administered intravenously according to protocol.

  • DocetaxelDrug

    Administered intravenously according to protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORR assessed by the investigator per RECIST v1.1Time frame: Up to 24months
  2. Safety reflected by AETime frame: Up to 24months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.